Last reviewed · How we verify
Paremyd (hydroxyamfetamine)
Paremyd (hydroxyamphetamine) is a small molecule adrenergic receptor agonist developed by PHARMICS, targeting the trace amine-associated receptor 1. It was approved by the FDA in 1969 for the treatment of dilated pupils. As an off-patent medication, its commercial status is likely generic. Key safety considerations include its potential effects on blood pressure and heart rate. Paremyd is a sympathomimetic agent that works by stimulating the adrenergic receptors in the eye.
At a glance
| Generic name | hydroxyamfetamine |
|---|---|
| Sponsor | Pharmics |
| Drug class | Adrenergic Receptor Agonist |
| Target | Trace amine-associated receptor 1 |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
| First approval | 1969 |
| Annual revenue | 172 |
Approved indications
- Dilated pupil
Common side effects
- Transient stinging
- Dryness of the mouth
- Blurred vision
- Photophobia
- Corneal staining
- Tachycardia
- Headache
- Allergic reactions
- Nausea
- Vomiting
- Pallor
- Muscle rigidity
Serious adverse events
- Increased intraocular pressure
- Psychotic reactions
- Behavioral disturbances
- Vasomotor collapse
- Cardiorespiratory collapse
- Myocardial infarction
- Ventricular fibrillation
- Significant hypotensive episodes
- Death
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Paremyd CI brief — competitive landscape report
- Paremyd updates RSS · CI watch RSS
- Pharmics portfolio CI